Oppenheimer Asset Management Inc. Has $19.28 Million Stock Position in IDEXX Laboratories, Inc. $IDXX

Oppenheimer Asset Management Inc. lessened its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 10.3% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 30,170 shares of the company’s stock after selling 3,458 shares during the period. Oppenheimer Asset Management Inc.’s holdings in IDEXX Laboratories were worth $19,275,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of IDXX. Blalock Williams LLC bought a new stake in IDEXX Laboratories in the third quarter valued at approximately $590,000. New York State Common Retirement Fund lifted its position in shares of IDEXX Laboratories by 6.8% in the 3rd quarter. New York State Common Retirement Fund now owns 60,225 shares of the company’s stock worth $38,477,000 after purchasing an additional 3,820 shares during the period. Arkadios Wealth Advisors bought a new stake in shares of IDEXX Laboratories in the 2nd quarter valued at $405,000. Mediolanum International Funds Ltd increased its position in shares of IDEXX Laboratories by 14.5% during the third quarter. Mediolanum International Funds Ltd now owns 38,761 shares of the company’s stock worth $24,441,000 after buying an additional 4,909 shares during the period. Finally, Principal Financial Group Inc. raised its stake in IDEXX Laboratories by 16.7% during the third quarter. Principal Financial Group Inc. now owns 1,315,722 shares of the company’s stock worth $840,638,000 after buying an additional 187,967 shares during the last quarter. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts have commented on IDXX shares. Jefferies Financial Group reaffirmed a “buy” rating and set a $830.00 price target on shares of IDEXX Laboratories in a research report on Tuesday, November 4th. UBS Group cut their target price on IDEXX Laboratories from $750.00 to $730.00 and set a “neutral” rating on the stock in a research report on Tuesday, February 3rd. JPMorgan Chase & Co. raised their target price on IDEXX Laboratories from $675.00 to $775.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 4th. Wall Street Zen upgraded IDEXX Laboratories from a “buy” rating to a “strong-buy” rating in a report on Saturday. Finally, BTIG Research cut their price target on IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating on the stock in a report on Tuesday, February 3rd. Seven research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, IDEXX Laboratories presently has a consensus rating of “Moderate Buy” and an average target price of $777.78.

IDEXX Laboratories Stock Performance

NASDAQ IDXX opened at $644.61 on Monday. The company has a market cap of $51.47 billion, a P/E ratio of 49.32, a PEG ratio of 3.93 and a beta of 1.67. The company has a fifty day simple moving average of $693.74 and a 200 day simple moving average of $665.85. The company has a current ratio of 1.23, a quick ratio of 0.90 and a debt-to-equity ratio of 0.23. IDEXX Laboratories, Inc. has a 12-month low of $356.14 and a 12-month high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Monday, February 2nd. The company reported $3.08 earnings per share for the quarter, beating analysts’ consensus estimates of $2.93 by $0.15. The firm had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.07 billion. IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. The business’s quarterly revenue was up 14.3% compared to the same quarter last year. During the same period last year, the firm earned $2.53 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. Sell-side analysts predict that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.